<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00373269</url>
  </required_header>
  <id_info>
    <org_study_id>3866 4187</org_study_id>
    <nct_id>NCT00373269</nct_id>
  </id_info>
  <brief_title>Procoagulant Effects of Hyperglycemia After Acute Stroke: A Pilot Study</brief_title>
  <official_title>Procoagulant Effects of Hyperglycemia After Acute Stroke: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Temple University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Temple University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Between twenty and fifty percent of people who have acute stroke have hyperglycemia (high
      blood sugar) with it. The purpose of this study is to examine the relationships between
      diabetes mellitus, hyperglycemia,whole blood tissue factor procoagulant activity (TF-PCA) and
      plasma factorVIIa (FVIIa) in ten patients with type 2 diabetes mellitus and 11 non-diabetic
      patients at baseline and 6, 12, 24, and 48 hours (h) after presentation for acute stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to examine the relationships between diabetes mellitus,
      hyperglycemia,whole blood tissue factor procoagulant activity (TF-PCA) and plasma factorVIIa
      (FVIIa) in ten patients with type 2 diabetes mellitus and 11 non-diabetic patients at
      baseline and 6, 12, 24, and 48 hours (h) after presentation for acute stroke.

      Patients presenting to the Emergency Department with ongoing stroke symptoms and neurologic
      deficit less than 24 hours (h) duration were screened for inclusion into the study. Stroke
      patients were grouped in terms of diabetes status as determined by past medical history.
      Stroke diagnosis was confirmed with brain magnetic resonance imaging (MRI). Clinical care,
      including the acute management ofstroke and hyperglycemia, was done at the discretion of the
      Neurology service not involved in the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2001</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>FVIIa</measure>
    <time_frame>Baseline</time_frame>
    <description>FVIIa levels were compared between the normoglycemic and hyperglycemic subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TF-PCA</measure>
    <time_frame>Baseline</time_frame>
    <description>TF-PCA levels compared between normoglycemic and hyperglycemic subjects.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">21</enrollment>
  <condition>Ischemic Stroke</condition>
  <condition>Hyperglycemia</condition>
  <arm_group>
    <arm_group_label>Diabetic subject</arm_group_label>
    <description>Subjects with acute stroke, hyperglycemia and history of diabetes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normoglycemic Control</arm_group_label>
    <description>Subjects with acute stroke and normal blood glucose.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients presenting to the Emergency Department with acute ischemic stroke within 12 hours
        of onset of symptoms.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged &gt; 18 years presenting to the Emergency Department with symptoms of acute
             ischemic stroke will be included for study.

          -  Acute stroke patients with normal blood glucose levels and patients with fingerstick
             blood glucose level of greater than or equal to 150 mg/dl will be eligible for study.

          -  Acute Stroke will be defined as an acute disturbance of cerebral function of presumed
             vascular origin causing a neurological deficit of less than 24 hours duration.

          -  Patients must have an NIH Stroke Scale Score of 4 to 23. Patients awakening with
             symptoms of stroke will be considered to have had their stroke at the time when last
             awake without symptoms.

        Exclusion Criteria:

          -  Patients presenting after 24 hours of symptom onset. When the actual time of onset is
             unknown, the time when last observed to be symptom-free will be used.

          -  Patients with NIH scale of less than 4 or greater than 23.

          -  Complete or substantial resolution of symptoms before randomization.

          -  Patients with a previously disabling stroke (modified Rankin score &gt; 3)

          -  Patients with other systemic disease such as infection (eg pneumonia, etc)

          -  Patients with hemorrhage visualized on CT.

          -  Patients who are unwilling or unable to give informed consent, or for whom a legally
             authorized representative is not able to consent.

          -  Pregnant patients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nina T Gentile, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Temple University</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2006</study_first_submitted>
  <study_first_submitted_qc>September 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2006</study_first_posted>
  <results_first_submitted>November 4, 2016</results_first_submitted>
  <results_first_submitted_qc>November 4, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 4, 2017</results_first_posted>
  <last_update_submitted>January 11, 2017</last_update_submitted>
  <last_update_submitted_qc>January 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute ischemic stroke</keyword>
  <keyword>Stroke</keyword>
  <keyword>Hyperglycemia</keyword>
  <keyword>Procoagulation</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Blood coagulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Normoglycemic Control</title>
          <description>Subjects with acute ischemic stroke and normal blood glucose.</description>
        </group>
        <group group_id="P2">
          <title>Hyperglycemic Subjects</title>
          <description>Subjects with acute ischemic stroke and hyperglycemia.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Normoglycemic</title>
          <description>Subjects with acute ischemic stroke and normal blood glucose.</description>
        </group>
        <group group_id="B2">
          <title>Hyperglycemic</title>
          <description>Subjects with acute ischemic stroke and hyperglycemia.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.9" spread="17.7"/>
                    <measurement group_id="B2" value="63.5" spread="9.2"/>
                    <measurement group_id="B3" value="64.2" spread="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>FVIIa</title>
        <description>FVIIa levels were compared between the normoglycemic and hyperglycemic subjects.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normoglycemic Control</title>
            <description>Subjects with acute ischemic stroke and normal blood glucose.</description>
          </group>
          <group group_id="O2">
            <title>Hyperglycemic Subjects</title>
            <description>Subjects with acute ischemic stroke and hyperglycemia.</description>
          </group>
        </group_list>
        <measure>
          <title>FVIIa</title>
          <description>FVIIa levels were compared between the normoglycemic and hyperglycemic subjects.</description>
          <units>mU/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.7" spread="33.3"/>
                    <measurement group_id="O2" value="124.4" spread="35.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TF-PCA</title>
        <description>TF-PCA levels compared between normoglycemic and hyperglycemic subjects.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normoglycemic Control</title>
            <description>Subjects with acute ischemic stroke and normal blood glucose.</description>
          </group>
          <group group_id="O2">
            <title>Hyperglycemic Subjects</title>
            <description>Subjects with acute ischemic stroke and hyperglycemia.</description>
          </group>
        </group_list>
        <measure>
          <title>TF-PCA</title>
          <description>TF-PCA levels compared between normoglycemic and hyperglycemic subjects.</description>
          <units>U/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183.5" spread="63.1"/>
                    <measurement group_id="O2" value="118.1" spread="56.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Serious and Other (Not Including Serious) Adverse Events were not collected/assessed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Diabetic Subject</title>
          <description>Subjects with acute stroke, hyperglycemia and history of diabetes.</description>
        </group>
        <group group_id="E2">
          <title>Normoglycemic Control</title>
          <description>Subjects with acute stroke and normal blood glucose.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Nina T. Gentile</name_or_title>
      <organization>Temple University</organization>
      <phone>215-707-8402</phone>
      <email>ngentile@temple.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

